Premium
Pharmacokinetics and beta‐blocking effects of timolol in poor and extensive metabolizers of debrisoquin
Author(s) -
McGourty John C,
Silas Joseph H,
Fleming Jude J,
McBurney Alan,
Ward John W
Publication year - 1985
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1985.195
Subject(s) - timolol , pharmacokinetics , blockade , pharmacology , chemistry , significant difference , plasma concentration , medicine , surgery , intraocular pressure , receptor
We studied the pharmacokinetics and β‐blocking effects of a single, oral 20 mg dose of timolol in six poor metabolizers (PMs) and six extensive metabolizers (EMs) of debrisoquin. The plasma timolol concentration was significantly higher in PMs than in EMs. There was a fourfold difference in mean AUC (1590 ± 1133 vs. 394 ± 239 ng · hr/ml; P < 0.01) and a twofold difference in mean t ½ (7.5 ± 3 vs. 3.7 ± 1.7 hours; P < 0.01), reflecting differences in oral clearance (13.1 ± 7.8 vs. 48.5 ± 23.2 L/hr; P < 0.01). The degree of β‐blockade was greater in PMs than in EMs at 12 hours (30.9% vs. 18.2%; P < 0.05) and at 24 hours (28.3% vs. 13.1%; P < 0.05). In the group as a whole the metabolic ratio correlated positively with both kinetic data and β‐blockade, but some overlap was observed. Hence timolol metabolism appears to be subject to debrisoquin‐type polymorphism, which results in interphenotypic variation in plasma concentration and β‐blocking effect. Clinical Pharmacology and Therapeutics (1985) 38 , 409–413; doi: 10.1038/clpt.1985.195